| 1. |
- Ekman, Agneta, 1961, et al.
(författare)
-
Low density and high affinity of platelet [3H]paroxetine binding in women with bulimia nervosa.
- 2006
-
Ingår i: Psychiatry research. - : Elsevier BV. - 0165-1781 .- 1872-7123. ; 142:2-3, s. 219-23
-
Tidskriftsartikel (refereegranskat)abstract
- Impaired serotonin transmission has been suggested to be implicated in the pathophysiology of bulimia nervosa. As an indirect measure of brain serotonergic activity, the binding of tritiated ligands to platelet serotonin transporters has been studied in bulimia nervosa as well as in other putatively serotonin-related psychiatric disorders. In this study, the density and affinity of platelet serotonin transporters were assessed in 20 women meeting the DSM-IV criteria for bulimia nervosa and in 14 controls without previous or ongoing eating disorder using [(3)H]paroxetine as a ligand. In comparison to controls, women with bulimia nervosa had a significantly reduced number of platelet binding sites (B(max) = 721 +/- 313 vs. 1145 +/- 293 fmol/mg protein) and an increase in the affinity for the ligand demonstrated by a lower dissociaton constant (K(d) = 33 +/- 10 vs. 44 +/- 10 pM). A significant correlation between B(max) and K(d) values was found in patients but not in controls. Our results support the notion that bulimia nervosa is associated with a reduction in platelet serotonin transporter density. In addition, our study is the first to report that this reduced transporter density in women with bulimia nervosa is accompanied by an increase in the affinity of the transporter for the ligand.
|
|
| 2. |
- Halbreich, Uriel, et al.
(författare)
-
Are there differential symptom profiles that improve in response to different pharmacological treatments of premenstrual syndrome/premenstrual dysphoric disorder?
- 2006
-
Ingår i: CNS drugs. - 1172-7047. ; 20:7, s. 523-47
-
Tidskriftsartikel (refereegranskat)abstract
- Current evidence suggests that the accepted treatments for premenstrual syndrome (PMS)/premenstrual dysphoric disorder (PMDD) have similar overall efficacy. While these treatments are more effective than placebo, response rates associated with them are far from satisfactory (<60%), such that, irrespective of treatment modality, there remain a significant number of women who are unresponsive to current conventional pharmacological therapy. The available data on response rates of specific types of premenstrual symptoms to, or symptom profiles that are most amenable to, each treatment modality are limited and not well defined because most studies were not designed to assess specific symptom profiles. Those studies that have attempted to evaluate which symptom profiles respond to specific therapies have revealed variations within the individual modalities, as well as between the different modalities. It appears that suppression of ovulation ameliorates a broad range of behavioural as well as physical premenstrual symptoms. SSRIs are most effective for irritability and anxiety symptoms, with lesser efficacy for 'atypical' premenstrual symptoms. GABAergic compounds are most efficacious for anxiety and anxious/depressive symptoms, while dopamine agonists, particularly bromocriptine, are perhaps most efficacious for mastalgia. Overall treatment response rates may improve if treatments are targeted at well-defined subgroups of patients. Re-analysis of available datasets from randomised clinical trials may shed more light on the notion that targeting women with specific premenstrual symptom profiles for specific treatment modalities would improve response rates beyond the current ceiling of approximately 60%. Such information would also improve understanding of the putative pathophysiological mechanisms underlying PMS and PMDD, and may point to a more specific diagnosis of these conditions.
|
|
| 3. |
- Henningsson, Susanne, 1977, et al.
(författare)
-
Interleukin-6 gene polymorphism -174G/C influences plasma lipid levels in women.
- 2006
-
Ingår i: Obesity (Silver Spring, Md.). - 1930-7381. ; 14:11, s. 1868-73
-
Tidskriftsartikel (refereegranskat)abstract
- Elevated levels of the pro-inflammatory cytokine interleukin-6 (IL-6) have been associated with cardiovascular risk factors. The objective of this study was to investigate potential associations between the promoter polymorphism IL-6 -174G/C and the following indices of metabolism: BMI, waist-to-hip ratio, and plasma levels of IL-6, cholesterol, low-density lipoprotein, triglycerides, high-density lipoprotein, leptin, and C-reactive protein in 252 42-year-old women and 245 51-year-old men. Subgroups were also studied 5 years later. The CC genotype of the IL-6 polymorphism was associated with lower levels of cholesterol and low-density lipoprotein (p < 0.001) in women. This finding was replicated in the follow-up, when a significant association between the CC genotype and low triglycerides was also observed. The association between the C allele and lipid pattern found in women was not found in men, where on the contrary, C carriers tended to display elevated triglycerides. IL-6 genotype was not associated with IL-6 plasma levels in either sample. The results suggest different effects of the IL-6 polymorphism on metabolic indices in women and men. None of the associations between IL-6 genotype and lipid pattern seemed to result from an effect of the polymorphism on IL-6 plasma levels.
|
|
| 4. |
- Yonker, Julie E, et al.
(författare)
-
Negative association of testosterone on spatial visualization in 35 to 80 year old men.
- 2006
-
Ingår i: Cortex; a journal devoted to the study of the nervous system and behavior. - 0010-9452. ; 42:3, s. 376-86
-
Tidskriftsartikel (refereegranskat)abstract
- Androgens have been linked to visuospatial ability. We examined the relationship between serum free testosterone (T) levels and spatial visualization ability in a population-based sample of 450 healthy men between the ages of 35 and 80 years. They were tested on block design and Mini Mental State Examination (MMSE) draw-a-figure, as well as tasks assessing episodic memory, semantic memory, procedural memory, and verbal fluency. Blood was analyzed for free T and estradiol. Participants were grouped into high or low free T based on age-specific median values. Participants with low free T performed at a superior level on both the block design task and draw-a-figure task as compared to participants with high free T. The results are discussed within the scant body of research on androgens and cognition in men.
|
|
| 5. |
- Yonker, Julie E, et al.
(författare)
-
Verified hormone therapy improves episodic memory performance in healthy postmenopausal women.
- 2006
-
Ingår i: Neuropsychology, development, and cognition. Section B, Aging, neuropsychology and cognition. - Hove : Informa UK Limited. - 1382-5585 .- 1744-4128. ; 13:3-4, s. 291-307
-
Tidskriftsartikel (refereegranskat)abstract
- Studies of hormone therapy (HT) and cognition have yielded conflicting results. The aim of this observational study was to examine the effect of estradiol, via serum verified HT (estradiol, estriol, progesterone) and endogenous estradiol, on 108 healthy postmenopausal women's cognitive performance. The results demonstrated that the 43 HT-users performed at a significantly higher level than non-users on episodic memory tasks and on a verbal fluency task, whereas HT-users and non-users did not differ on tasks assessing semantic memory and spatial visualization. In addition, there was a positive relationship between serum estradiol level and episodic memory performance, indicating that postmenopausal HT is associated with enhanced episodic memory and verbal fluency, independent of age and education. These observational results suggest that HT use may be sufficient to exert small, yet positive effects on female sensitive cognitive tasks. Hormone therapy compliance and formulation is discussed as confounding factors in previous research.
|
|
